Swallowing Disorders in Schizophrenia
AbstractDisorders of swallowing are poorly characterized but quite common in schizophrenia. They are a source of considerable morbidity and mortality in this population, generally as a result of either acute asphyxia from airway obstruction or more insidious aspiration and pneumonia. The death rate from acute asphyxia may be as high as one hundred times that of the general population. Most swallowing disorders in schizophrenia seem to fall into one of two categories, changes in eating and swallowing due to the illness itself and changes related to psychotropic medications. Behavioral changes related to the illness are poorly understood and often involve eating too quickly or taking inappropriately large boluses of food. Iatrogenic problems are mostly related to drug-induced extrapyramidal side effects, including drug-induced parkinsonism, dystonia, and tardive dyskinesia, but may also include xerostomia, sialorrhea, and changes related to sedation. This paper will provide an overview of common swallowing problems encountered in patients with schizophrenia, their pathophysiology, and management. While there is a scarcity of quality evidence in the literature, a thorough history and examination will generally elucidate the predominant problem or problems, often leading to effective management strategies.
CONCLUSIONS: HIV hospitalizations are largely preventable with appropriate treatment and adherence. Additional efforts to improve retention in HIV care that address comorbidities of PLWHA are needed. PMID: 29913100 [PubMed - as supplied by publisher]
Authors: Ocheretyaner ER, Park TE Abstract INTRODUCTION: The resistance to current antimicrobial agents, including fluoroquinolones, has continued to grow among various pathogens indicating a need for new antimicrobials to combat multi-drug resistant (MDR) organisms. In June 2017, delafloxacin received approval by the United States Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults caused by designated susceptible bacteria. Areas covered: This review describes the pharmacology, pharmacodynamics, pharmacokinetics, product information, efficacy, an...
Conclusions: The relatively low level of inflammatory saliva cytokines observed in the current study (negative z scores versus normative data with medium effect sizes) indicates that evaluation of blood inflammatory levels in trichotillomania versus matched controls would be valuable in future work. If a hypoinflammatory state is confirmed using blood samples, this would differentiate trichotillomania from other mental disorders (such as OCD, schizophrenia, and depression), which have typically been linked with high inflammatory measures in the literature, at least in some cases.Neuropsychobiology
Condition: Parkinson Disease, Essential Tremors and Dystonia Intervention: Device: Deep Brain Stimulation Sponsor: Assiut University Not yet recruiting
Authors: Farah R, Khamisy-Farah R, Makhoul N Abstract BACKGROUND: Accurate diagnosis of community acquired pneumonia (CAP) is crucial to its proper management and to combating antibiotic resistance. Levels of C-reactive protein (CRP) have been shown to distinguish pneumonia from other pathological conditions and can be used to control the severity of infection during admission. OBJECTIVES: To investigate an association between consecutive measurements of CRP and the severity of CAP in hospitalized patients. METHODS: A total of 500 patients with CAP were admitted to the hospital. Traditional markers of infla...
(McGill University) Scientists at the Montreal Neurological Institute and Hospital (The Neuro) and McGill University have identified novel genes associated with a specific form of schizophrenia.
Conclusions Reduced temporal variability and connectivity strength between key regions of eloquent language cortex may represent a mechanism for AH in schizophrenia.
Conclusion Syndecan-1, but not endocan, was associated with neutrophil activation and was the best EG biomarker predictor of adverse clinical outcomes.
Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivityTreatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity, Published online: 19 June 2018; doi:10.1038/s41380-018-0106-5Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity
AbstractPurpose of ReviewCannabis and cannabinoids have been used medically and recreationally for thousands of years and recently there has been a growing body of research in this area. With increased access now that medical marijuana is available in many jurisdictions, patients and providers want to know more about the evidence for benefits and risks of cannabinoid use. This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of cannabinoids for treating spasticity and pain associated with multiple sclerosis (MS), and a discussion of possible d...